Trump Administration's 'Historic' Drug Pricing Move: Pfizer to Sell Discounted Meds via TrumpRx
The Trump administration has announced an 'historic' move in drug pricing policy. TrumpRx, a virtual marketplace for discounted pharmaceuticals, is set to launch in 2026. Pfizer has agreed to sell most of its medications to Medicare at 'most favored nation' prices, with some drugs available at even lower prices on the TrumpRx platform.
The agreement between the Trump administration and Pfizer, though confidential, will see Pfizer use the announced discounts as a benchmark for negotiating supplemental rebates in Medicare. Pfizer has disclosed several drugs, including Eucrisa, Duavee, Toviaz, Abrilada, and Xeljanz, that will be sold at most favored nation prices or lower on TrumpRx.
Most favored nation prices will be based on prices paid in other wealthy countries like Canada, France, Germany, Italy, Japan, the UK, Switzerland, and Denmark. The Trump administration expects more pharmaceutical companies to follow Pfizer's example, after sending letters to 17 leading companies requesting price reductions to match those paid abroad by September 29.
While the impact of TrumpRx on patients and Medicare payers is yet to be fully evaluated due to lack of critical details, the initiative is poised to bring significant changes to drug pricing in the US. With Pfizer leading the way, other pharmaceutical companies are expected to follow suit, potentially leading to substantial savings for patients and Medicare payers.
